- Jabil Inc. has completed the acquisition of Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), on February 3, 2025.
- The deal strengthens Jabil’s pharmaceutical solutions, adding expertise in aseptic filling, lyophilization, and oral solid dose manufacturing.
Jabil Inc. has completed the acquisition of Pharmaceutics International, Inc. (Pii), a CDMO specialising in aseptic filling, lyophilization, and oral solid dose manufacturing. The transaction, finalised on February 3, 2025, enhances Jabil’s presence in pharmaceutical development and manufacturing.
With this acquisition, Jabil expands its Pharmaceutical Solutions offering, which includes auto-injectors, pen injectors, inhalers, and on-body pumps. The integration of Pii’s capabilities will enable Jabil to support both clinical and commercial drug manufacturing needs. Mike Mahaz, SVP, Global Business Units, Healthcare at Jabil, highlighted the strategic importance of the deal, stating, “Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain.”
Founded in 1994, Pii operates across a 360,000-square-foot campus in Hunt Valley, Maryland, with over 70 manufacturing rooms, including containment suites for high-potency compounds and hormones, dedicated spaces for oral solid dose products, and an aseptic facility for injectables. These assets will complement Jabil’s expertise in parenteral drug delivery, particularly in markets such as GLP-1 therapies.
James O’Gorman, Vice President, Pharmaceutical Solutions at Jabil, emphasised the acquisition’s role in driving growth, stating, “The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil’s customer offering and support business growth potential as we enter the CDMO market.”
As part of Jabil, Pii will benefit from enhanced global infrastructure, automation, and supply chain efficiencies. John Fowler, President and CEO at Pii, described the move as a significant step forward, noting that Pii will leverage Jabil’s expertise to enhance drug development and manufacturing for its pharmaceutical partners and patients worldwide.